CytomX Therapeutics Inc (CTMX) Just Recorded A Sigfniciant Increase

September 17, 2017 - By Migdalia James

The stock of CytomX Therapeutics Inc (NASDAQ:CTMX) is a huge mover today! The stock increased 4.28% or $0.71 on September 15, reaching $17.31. About 1.15 million shares traded or 298.68% up from the average. CytomX Therapeutics Inc (NASDAQ:CTMX) has risen 50.10% since September 17, 2016 and is uptrending. It has outperformed by 33.40% the S&P500.
The move comes after 5 months positive chart setup for the $638.17M company. It was reported on Sep, 17 by We have $18.52 PT which if reached, will make NASDAQ:CTMX worth $44.67 million more.

Wall Street await CytomX Therapeutics Inc (NASDAQ:CTMX) to release earnings on November, 2. Analysts forecast earnings per share of $-0.10, up exactly $0.30 or 75.00 % from 2014’s $-0.4 EPS. After posting $-0.69 EPS for the previous quarter, CytomX Therapeutics Inc’s analysts now forecast -85.51 % EPS growth.

CytomX Therapeutics Inc (NASDAQ:CTMX) Ratings Coverage

Among 3 analysts covering CytomX Therapeutics (NASDAQ:CTMX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. CytomX Therapeutics had 4 analyst reports since November 2, 2015 according to SRatingsIntel. Oppenheimer initiated it with “Outperform” rating and $17 target in Monday, November 2 report. The firm has “Outperform” rating given on Monday, November 2 by Cowen & Co. The rating was downgraded by Oppenheimer on Tuesday, January 3 to “Perform”. The firm has “Buy” rating by Jefferies given on Monday, November 2.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The company has market cap of $638.17 million. The Firm uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. It currently has negative earnings. The Company’s pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.